Last reviewed · How we verify
AMG 386, paclitaxel and carboplatin
Angiopoietin-2 inhibitor
Angiopoietin-2 inhibitor Used for Ovarian cancer, Breast cancer.
At a glance
| Generic name | AMG 386, paclitaxel and carboplatin |
|---|---|
| Sponsor | Amgen |
| Drug class | Angiopoietin-2 inhibitor |
| Target | Angiopoietin-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AMG 386 is a recombinant human angiopoietin-2 (Ang-2) decoy receptor that inhibits angiopoietin-2 activity, thereby inhibiting angiogenesis. This mechanism is thought to be beneficial in treating various cancers.
Approved indications
- Ovarian cancer
- Breast cancer
Common side effects
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer (PHASE3)
- Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG 386, paclitaxel and carboplatin CI brief — competitive landscape report
- AMG 386, paclitaxel and carboplatin updates RSS · CI watch RSS
- Amgen portfolio CI